Tolarex/Enlivex
COVID-19
Enlivex: Has developed a medication that could help treat severe symptoms of covid-19 including catastrophic organ failure.
Company Name
Enliex
Year Company was Founded
2005
About the Company
Enlivex Therapeutics R&D, a clinical-stage company focused on specialized cell immunotherapy, develops and commercializes an allogeneic drug pipeline for rebalancing immune hyper-responses.
The company’s Allocetra aims to effectively treat numerous acute conditions by using the body’s native mechanisms to restore rather than suppress immune balance. Enlivex aims to reshape the way immune, autoimmune, and inflammatory conditions are thought of and treated.
In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma, a stock market-listed clinical-stage company developing treatments for rare genetic diseases. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Links to Products
Allocetra™ is an innovative immunotherapy that is being developed to rebalance life-threatening hyperactivity of the immune system, using the immune system’s own natural regulation mechanisms. By intelligently engaging macrophages and dendritic cells, Allocetra™ is designed to avert cytokine storms and restores safe immune balance – without suppressing the immune system
Company Website
Video Links
https://www.youtube.com/channel/UCGJI8b2YMny7Gxu3mMrQlPg
Social Media Links
https://www.linkedin.com/company/enlivex-therapeutics-nasdaq-enlv/
